biosimilars
PBS clarifies biosimilar warning codes
Warning codes not always a block on biosimilar substitution, Pharmaceutical Benefits Scheme (PBS) says Pharmacists receiving PBS warning reason codes 162 and 163 when substituting a biosimilar for a reference …
Keeping up with biosimilars
Pharmacy has a prominent role in the supply and provision of biosimilar medicines, and the profession has been slow to come to terms with this. Is the situation now changing? …
The inevitable rise of biosimilars
In the latest in our series based on 2017 UTS Pharmacy Barometer results, John Montgomery looks at how pharmacists view the riding tide of biosimilar medicines There’s little doubt biosimilar …
Patents extended under revived TPP?
The ACTU has attacked the government over the revived TPP, claiming it would drive up drug prices ACTU president Ged Kearney says that the Trans Pacific Partnership, which is set …
Warning on biosimilar burden
A higher than usual degree of pharmacovigilance is required when patients are switched to new biosimilar medications, say Australian experts Writing in the latest Australian Prescriber two pharmacy academics have stressed …